Phase 2 N=179 Topical Rapamycin to Erase Angiofibromas in TSC
Angiofibromas · Tuberous Sclerosis
Primary: Change From Baseline in the Facial Angiofibroma Grading Scale (AGS) Score — -13.89; -12.71; -1.39 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=27 Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
Port Wine Stain
Primary: Change From Baseline in a* and E at 8 Weeks — 1.27; 0.43; 4.08; 2.59 units on a scale
Phase 3 N=107 Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex
Facial Angiofibroma · Tuberous Sclerosis
Primary: Percentage of Participants Obtaining Successful Treatment — 4; 3; 2 Participants
Phase 2 N=36 RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS
Nonmalignant Neoplasm · Tuberous Sclerosis · Lymphangioleimyomatosis
Primary: Objective Response Rate — 44.4 percentage of participants
N/A N=22 Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment
Port-Wine Stain
Primary: Percent Change in Blanching of Port Wine Stain — 6; 5 percentage
N/A N=357 Hemangioma Associated With High Rates of Morbidity
Hemangioma
Primary: MRI/MRA of Head/Neck/Chest. — 357 participants
Phase 3 N=118 Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
Tuberous Sclerosis Complex (TSC) · Lymphangioleiomyomatosis (LAM)
Primary: Angiomyolipoma Response Rate as Per Central Radiology Review — 41.8; 0; 58.0 Percentage of Participants — p=<0.0001
Phase 2 N=10 Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
Hereditary Hemorrhagic Telangiectasia
Primary: Change in Lesion Area of Treated Telangiectasia. — -6; -8 mm^2
Phase 4 N=40 Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.
Renal Angiomyolipoma
Primary: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 40; 39; 6; 2 Participants
N/A N=37 Efficacy of 1540 Nanometer Erbium Glass Laser to Improve Benign Dermatofibromas
Dermatofibroma of Skin
Primary: Modified Patient and Observer Scar Assessment Scale Color Component Comparing Change From Baseline to Week 12. — -2.33 score on a scale
N/A N=10 Combination Gel and Vascular ND in Mild to Moderate Rosacea
Rosacea
Primary: IGA of Improvement — 3.1; 3.5 units on a scale
N/A N=22 Clinical Evaluation of the Treatment of Spider Angioma
Spider Angioma
Primary: Physician's Global Assessment Scale for Improvement of Spider Angioma — 4.5 score on a scale
N/A N=10 Dermatosis Papulosa Nigra
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
Phase 2 N=61 Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies
Kaposiform Hemangioendotheliomas · Tufted Angioma · Capillary Venous Lymphatic Malformation
Primary: Overall Response by Radiologic Evaluation, Quality of Life Assessment, and Functional Impairment Score — 47; 7; 3 Participants
N/A N=22 Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
Erythematotelangiectatic Rosacea · Papulopustular Rosacea
Primary: Degree of Improvement in Erythematotelangiectatic Rosacea and Papulopustular Rosacea — 2.114; 2.088 score on a scale
Phase 2 N=24 Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T
Neurofibromatosis 1
Primary: 3D Photographic Measurement of Surface Volume of Cutaneous Neurofibroma Lesion — 32.54; 33.93 mm^3
Phase 2 N=11 Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
Cutaneous Neurofibroma · Neurofibromatosis Type 1 · Optic Nerve Glioma
Primary: Median Best Response of Cutaneous Neurofibromas in Participants With at Least One Restaging Evaluation — -28.5 percent change
N/A N=15 Comparison of Electrodessication, Potassium Titanyl Phosphate (KTP) Laser and Pulsed Dye Laser for Treatment of Cherry Angiomata
Cherry Angioma
Primary: Mean Changes in Color, Texture, and Size of Cherry Angiomata From Baseline to 3 Months After the Second Treatment by Treatment Type as Assessed by Blinded Raters — 5.27…
Phase 1 N=1 Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)
Neurofibromatoses
Primary: Part 1: Photosensitizer Uptake and Conversion to Protoporphyrin IX — 304 Densitometry units/micrometer squared — p=0.0001
N/A N=115 PicoWay™ 730 Resolve Fusion for Benign Pigmented Lesions and Wrinkles
Benign Pigmented Lesions · Facial Wrinkles
Primary: Change in Wrinkles From Baseline to 12 Weeks Post-study Treatment Assessed by Blinded Photographic Evaluation Using 9-Point Fitzpatrick Wrinkle Scale
Phase 2 N=3 Afamelanotide in Patients Suffering With Acne Vulgaris
Acne Vulgaris
Primary: The Change in Number of Facial Inflammatory Acne-related Lesions. — 46; 23.7 Lesions
Phase 2 N=9 Medical Treatment of "High-Risk" Neurofibromas
Neurofibromatosis 1
Primary: Improvement of Symptoms and Pain — 9 Participants
Phase 2 N=32 Bevacizumab in Treating Patients With Angiosarcoma
Sarcoma
Primary: Median Progression-free Survival of Patients Treated With the Study Drug as Defined by RECIST Criteria. — 12.4 Weeks
Phase 2 N=72 PAZOPANIB Efficacy and Tolerance in Desmoids Tumors
Progressive Desmoids Tumors
Primary: Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate). — 84.8; 45.0…
Phase 2 N=29 Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
Adult Angiosarcoma · Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma
Primary: PFS Rate — 54.6 percentage of patients